Building the Bulletproof Net Startup Post 1

31 05 2011

1. People
They Matter Most

After all the market-cap comparison, strategy debates, patent filings, and the news media’s breathless coverage of seemingly every dot-com IPO, the success of Internet startups comes down to the ultimate Darwinian business differentiator: people. Yes, size matters – along with funding, a catchy name, great advertising, capital, technology, structure, partnerships. But people matter most. Read the rest of this entry »



Bad Amy Part 2

23 05 2011

A few minutes later I shoved my barstool further into the corner to make room for Bob, an obvious tourist with generously moussed gray-hair, decked out in a brand new Hawaiian shirt. After a short negotiation where I trotted out flirting skills I thought I had lost a hundred years ago, Bob agreed to buy me a drink as payment of “rent” on the space I had made for him. I proudly shared the drink with Amy and paid close attention in case she was going to offer more tips on being bad. Read the rest of this entry »



Bad Amy Part 1

16 05 2011

“A vacation spent alone months after the man I loved succumbed to a mid-life crisis and broke my heart. ” Then the author meets Bad Amy. Inspiration and rejuvenation can occur when we try on new behavior. Read the rest of this entry »



Hepatitis C

6 05 2011

Symposium on Emerging Therapies for Chronic Viral Hepatitis

Introduction

The symposium on ?Emerging Therapies for Chronic Viral Hepatitis”, held October 2-4, 1998 in Montreal, Canada was hopefully the first in a series. The main corporate sponsors were Biochem Pharma Inc., OSI Pharmacenticals, GlaxoWellcome and Schering Plough Canada. Other sponsors included the Medical Research Council of Canada. The symposium was chaired by Dr. Lorne Tyrrell (University of Alberta, Canada) and was attended by approximately 205 participants from 17 countries. The meeting was targeted towards both clinicians and basic understanding hepatitis C virus (HCV) and hepatitis B virus (HBV) induced chronic hepatitis. Read the rest of this entry »